“Clinical Response and Safety of Alternating Daily Dosage of Crizotinib due to Side Effects in Advanced NSCLC patient harboring ROS1-rearrangement: A Case Report”, J Respirol Indones, vol. 43, no. 2, pp. 111–115, Apr. 2023, doi: 10.36497/jri.v43i2.201.